




Rezūm™ Water Vapour Therapy

INTRODUCTION

- Rezūm™ Water Vapour Therapy is an innovative minimally invasive surgical treatment (MIST) to reduce prostate tissue volume associated with benign prostatic hyperplasia (BPH), including hyperplasia of the lateral lobes, central zones and median lobe for patients that want to avoid taking medication¹⁻³
- The latest evidence demonstrates the durability and safety profile of Rezūm Therapy, which improves symptoms of BPH and preserves sexual function through 5 years^{1,4}



THE REZŪM SYSTEM: FEATURES AND BENEFITS



*Measured from the time of device insertion to the time the device is removed from the patient.

PROVEN TREATMENT


Sustained symptom improvement in clinical outcomes through 5 years¹



Data from the 5-year pivotal study conducted in patients with moderate-to-severe lower urinary tract symptoms secondary to BPH.


High patient satisfaction for patients that want to avoid medication

Rezūm Therapy is an alternative to medication and could be considered a first-line treatment option



Tissue resorption

The convective water vapour (steam) reduces the volume of the prostate^{*5,12}



Magnetic resonance images.

*Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

KEY MESSAGES

- Rezūm Therapy is a versatile procedure that works for a wide range of BPH patients, including those with lateral and central lobe obstruction¹⁵
- It provides effective and durable clinical improvements with a low surgical retreatment rate^{1,16}
- The positive safety profile, durability, and maintenance of sexual function¹ make Rezūm Therapy an alternative to standard BPH management that could be considered a first-line therapy option

Potential risks associated with Rezūm Water Vapor Therapy include but are not limited to dysuria, hematuria, hematospermia, decrease in ejaculatory volume, urinary tract infection (UTI), and urinary frequency, retention or urgency. A complete list of indications, contraindications, warnings, precautions, and adverse events is included in the labelling provided with the device.

REFERENCES

1. McVary KT, Gittelman MC, Goldberg KA *et al.* Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol.* 2021; **206**: 715–24.
2. Benign prostatic hyperplasia (BPH) + Rezūm™ water vapor therapy. Key messages and Q&A. Available at: https://www.bostonscientific.com/content/dam/bostonscientific/uro-wh/general/bph-resources/rezum-pdf/URO-699302-AA_BPH-Rezum-Key-Messages-and-FAQs-FINAL.pdf. [Accessed 28/07/22].
3. McVary KT, Rogers T, Roehrborn CG. Rezum water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology.* 2019; **126**: 171–9.
4. McVary KT, El-Arabi A, Roehrborn C. Preservation of sexual function 5 years after water vapor thermal therapy for benign prostatic hyperplasia. *Sex Med.* 2021; **9**: 100454.
5. Dixon CM, Rijo Cedano E, Mynderse LA *et al.* Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum® system: Evaluation of acute ablative capabilities in the human prostate. *Res Rep Urol.* 2015; **7**: 13–8.
6. Gravas S, Cornu JN, Gacci M *et al.* EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). European Association of Urology 2021. Available at: <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>. [Accessed 28/07/22].
7. National Institute for Health and Care Excellence (NICE). Rezum for treating benign prostatic hyperplasia. Available at: <http://www.pchurology.co.uk/governance/rezum.pdf>. [Accessed 28/07/22].
8. Lerner LB, McVary KT, Barry MJ *et al.* Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART II – surgical evaluation and treatment. *J Urol.* 2021; **206**: 818–26.
9. McVary KT, Chughtai B, Miller LE *et al.* Putting patients ahead by leaving nothing behind: An emerging treatment paradigm in minimally invasive surgical therapy for benign prostatic hyperplasia. *Med Devices (Auckl).* 2021; **14**: 59–64.
10. Ulchaker JC, Martinson MS. Cost-effectiveness analysis of six therapies for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Clinicoecon Outcomes Res.* 2018; **10**: 29–43.
11. Roehrborn CG, Barkin J, Gange SN *et al.* Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol.* 2017; **24**: 8802–13.
12. Mynderse LA, Hanson D, Robb RA *et al.* Rezum system water vapor treatment for lower urinary tract symptoms/benign prostatic hyperplasia: Validation of convective thermal energy transfer and characterization with magnetic resonance imaging and 3-dimensional renderings. *Urology.* 2015; **86**: 122–7.
13. Data on file. Boston Scientific.
14. Mooney R, Goldberg K, Wong D *et al.* Convective radio frequency thermal therapy for treatment of benign prostatic hyperplasia: Single office experience with 255 patients over 4 years. *Urol Pract.* 2020; **7**: 28–33.
15. Woo HH, Gonzalez RR. Perspective on the Rezum® System: A minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. *Med Devices (Auckl).* 2017; **10**: 71–80.
16. Gupta N, Rogers T, Holland B *et al.* Three-year treatment outcomes of water vapor thermal therapy compared to doxazosin, finasteride and combination drug therapy in men with benign prostatic hyperplasia: Cohort data from the MTOPS trial. *J Urol.* 2018; **200**: 405–13.

CAUTION: The law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Information for use only in countries with applicable health authority product registrations.

Products shown for **INFORMATION** purposes only and may not be approved or for sale in certain countries.

This material is not intended for use in France.

Please check availability with your local sales representative or customer service.

UROPH-1381903-AA

**Boston
Scientific**
Advancing science for life™

www.bostonscientific.eu

© 2022 Boston Scientific Corporation
or its affiliates. All rights reserved.
DINURO2456EB